Drug resistance patterns of Mycobacterium tuberculosis in Riyadh, Saudi Arabia

International Journal of Tuberculosis and Lung Disease

Volumn 8, Issue 8, 2004, Pages 1007-1011

  Kordy, F N S ^a   Al Thawadi, S ^a   Alrajhi, Abdulrahman A ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

Drug resistance; Mycobacterium tuberculosis; Saudi Arabia

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; TUBERCULOSTATIC AGENT;

ADULT; ANTIBIOTIC RESISTANCE; BACTERIUM ISOLATE; CONTROLLED STUDY; DATA BASE; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MULTIDRUG RESISTANCE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRIORITY JOURNAL; RADIOMETRY; REVIEW; SAUDI ARABIA; TUBERCULOSIS; TUBERCULOSIS CONTROL;

ANTITUBERCULAR AGENTS; CHI-SQUARE DISTRIBUTION; FEMALE; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; SAUDI ARABIA; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 3543090872     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (24)

1. Espinal M A. Multidrug resistant tuberculosis: basis for the development of an evidence-based case-management strategy for MDR-TB for the WHO's DOTS Strategy. Proceeding of 1998 Meetings and Protocol Recommendations. Geneva, Switzerland: WHO, 1999. http://www.who.int/gtb/publications/mdrtb/PDF/who.tb.99. 260.pdf Accessed May 2004.
2. World Health Organization (WHO). Anti-tuberculosis drug resistance in the world. The WHO/IUATLD Global Project on Anti-Tuberculosis Drug Resistance Surveillance 1994-1997. Geneva, Switzerland: WHO, 1997. http://www.who.int/gtb/ publications/dritw/index.htm Accessed May 2004.
3. Centers for Disease Control and Prevention. Initial therapy for tuberculosis in the era of multidrug resistance-recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR 1993; 42(RR-7).
4. Vestal A L. Procedures for isolation and identification of mycobacterium. Atlanta, GA, USA: Centers for Disease Control and Prevention, 1975.
5. Kent P T, Kubica G P. Public health mycobacteriology: guide for the Level III Laboratory. Atlanta, GA, USA: US Department of Health and Human Services, Centers for Disease Control, USA, 1985.
6. Alrajhi A A, Al-Barrak A M. Mycobacterium tuberculosis susceptibility in Saudi Arabia. Saudi Med J 2002; 23: 1227-1231.
7. Manalo F, Tan F, Sbarbaro J A, Iseman M D. Community-based short-course treatment of pulmonary tuberculosis in a developing nation. Initial report of an eight-month, largely intermittent regimen in a population with a high prevalence of drug resistance. Am Rev Respir Dis 1990; 142: 1301-1305.
8. Schwoebel V, Lambregts-van Weezenbeek C S, Moro M L, et al. Standardization of anti-tuberculosis drug resistance surveillance in Europe. Recommendations of a World Health Organization (WHO) and International Union Against Tuberculosis and Lung Disease (IUATLD) Working Group. Eur Respir J 2000; 16: 364-371.
9. Crofton J, Chaulet P. Guidelines for the management of drug-resistant tuberculosis. Global Tuberculosis Programme. Geneva, Switzerland: World Health Organization, 1997. http://www.who.int/gtb/publications/gmdrt/PDF/tb96_210.pdf Accessed May 2004.
10. Schiott C R, Engbaek H C, Vergmann B, et al. Resistant strains of Mycobacterium tuberculosis in the Gizan Area, Saudi Arabia. Ugeskrift for Laeger 1984; 146: 4024-4026.
11. Al-Orainy I O. Resistance to standard antituberculous drugs in Saudi Arabia. Saudi Med J 1986; 7: 363-368.
12. Al-Orainey I O, Saeed E S, El-Kassimi F A, al-Shareef N. Resistance to antituberculous drugs in Riyadh, Saudi Arabia. Tubercle 1989; 70: 207-210.
13. Chowdhury M N, Kambal A M. Mycobacterial resistance in a general hospital in Riyadh Saudi Arabia. Med Sci Res 1992; 20: 21-22.
14. Jarallah J S, Elias A K, Al-Hajjaj M S, et al. High rate of rifampicin resistance of Mycobacterium tuberculosis in the Taif region of Saudi Arabia. Tubercle Lung Dis 1992; 73: 113-115.
15. Ellis M E, Al-Hajjar S, Bukhari H, et al. High proportion of multi-drug resistant Mycobacterium tuberculosis in Saudi Arabia. Scand J Infect Dis 1996; 28: 591-595.
16. Al-Jama A A, Borgio F G, Al-Qatari K M. Patterns of resistance to antituberculous drugs in Eastern Province, Saudi Arabia. Saudi Med J 1999; 20: 927-930.
17. Khan M Y, Kinsara A J, Osoba A O, et al. Increasing resistance of M. tuberculosis to anti-TB drugs in Saudi Arabia. Int J Antimicrob Agents 2001; 17: 415-418.
18. El-Kassimi F A. The annual risk of tuberculosis infection used as predictor of the future incidence of smear-positive cases. Respir Med 1994; 88: 589-592.
19. Alrajhi A A, Abdulwahab S, Almodovar E, et al. Risk factors for drug-resistant Mycobacterium tuberculosis in Saudi Arabia. Saudi Med J 2002; 23: 305-310.
20. Espinal M A, Laszlo A, Simonsen L, et al. Global trends in resistance to antituberculosis drugs. N Engl J Med 2001; 344: 1294-1303.
21. Centers for Disease Control and Prevention. Progressing toward tuberculosis elimination in low-incidence areas of the United States: recommendations of the Advisory Council for the Elimination of Tuberculosis. MMWR 2002; 51 (RR-5).
22. Centers for Disease Control and Prevention. Treatment of Tuberculosis, American Thoracic Society, CDC, and Infectious Diseases Society of America. MMWR 2003; 52(No. RR-11).
23. American Thoracic Society. Control of tuberculosis in the United States. Am Rev Respir Dis 1992; 146: 1623-1633.
24. Dupon M, Texier-Maugein J, Leroy V, et al. Tuberculosis and HIV infection: a cohort study of incidence and susceptibility to antituberculous drugs, Bordeaux, 1985-1993. AIDS 1995; 9: 577-583.